
  
    
      
        Background_NNP
        Prostate_NNP cancer_NN is_VBZ the_DT most_RBS frequently_RB diagnosed_VBN
        visceral_NN cancer_NN in_IN the_DT United_NNP States_NNPS and_CC the_DT second_JJ leading_VBG
        cause_NN of_IN cancer_NN death_NN in_IN men_NNS [_NN 1_CD ]_NN ._. Unfortunately_RB ,_, there_EX
        are_VBP no_DT proven_VBN primary_JJ prevention_NN strategies_NNS for_IN prostate_NN
        cancer_NN and_CC no_DT curative_JJ treatments_NNS for_IN distant-stage_JJ cancers_NNS
        [_NN 2_CD 3_CD ]_NN ._. Consequently_RB ,_, cancer_NN control_NN efforts_NNS have_VBP focused_VBN
        on_IN detecting_VBG early-stage_JJ prostate_NN cancer_NN with_IN screening_NN
        tests_NNS and_CC then_RB aggressively_RB treating_VBG the_DT cancer_NN with_IN
        surgery_NN or_CC radiation_NN ._. The_DT most_RBS effective_JJ screening_NN test_NN is_VBZ
        the_DT prostate-specific_JJ antigen_NN (_( PSA_NNP )_) assay_NN ,_, which_WDT in_IN
        combination_NN with_IN digital_JJ rectal_NN examination_NN (_( DRE_NNP )_)
        substantially_RB enhances_VBZ the_DT cancer_NN detection_NN rate_NN [_NN 4_CD ]_NN ._.
        The_DT American_NNP Cancer_NNP Society_NNP and_CC the_DT American_NNP Urologic_NNP
        Association_NNP recommend_VB annual_JJ cancer_NN screening_NN with_IN PSA_NNP
        testing_NN and_CC digital_JJ rectal_NN examination_NN for_IN men_NNS with_IN life_NN
        expectancies_NNS greater_JJR than_IN 10_CD years_NNS [_NN 5_CD 6_CD ]_NN ._. However_RB ,_, the_DT
        United_NNP States_NNPS Preventive_NNP Services_NNPS Task_NNP Force_NNP and_CC the_DT
        American_NNP College_NNP of_IN Physicians_NNPS have_VBP not_RB endorsed_VBN routine_JJ
        screening_NN because_IN there_EX is_VBZ no_DT conclusive_JJ evidence_NN that_DT
        screening_NN and_CC treatment_NN reduce_VB morbidity_NN and_CC mortality_NN from_IN
        prostate_NN cancer_NN [_NN 7_CD 8_CD ]_NN ._. Another_DT concern_NN about_IN prostate_NN
        cancer_NN screening_NN is_VBZ uncertainty_NN about_IN the_DT diagnostic_JJ
        performance_NN of_IN PSA_NNP ._. The_DT available_JJ data_NN on_IN PSA_NNP testing_NN
        generally_RB come_VB from_IN urologic_JJ case_NN series_NN comprised_VBN of_IN
        volunteers_NNS responding_VBG to_TO advertisements_NNS for_IN screening_NN [_NN 9_CD
        10_CD 11_CD ]_NN ._. However_RB ,_, PSA_NNP screening_NN recommendations_NNS encompass_VB
        the_DT entire_JJ population_NN of_IN men_NNS at_IN risk_NN for_IN prostate_NN cancer_NN
        and_CC results_NNS from_IN the_DT urologic_JJ literature_NN may_MD not_RB be_VB fully_RB
        generalizable_JJ ._. We_PRP have_VBP not_RB found_VBN any_DT large_JJ community-based_JJ
        studies_NNS evaluating_VBG the_DT accuracy_NN of_IN PSA_NNP testing_NN ._.
        In_IN this_DT report_NN we_PRP link_VBP PSA_NNP testing_NN and_CC prostate_NN biopsy_NN
        data_NNS from_IN the_DT Albuquerque_NNP ,_, New_NNP Mexico_NNP metropolitan_JJ area_NN
        with_IN population-based_JJ cancer_NN registry_NN data_NNS collected_VBN by_IN the_DT
        New_NNP Mexico_NNP Tumor_NNP Registry_NNP (_( NMTR_NNP )_) ,_, a_DT participant_NN in_IN the_DT
        National_NNP Cancer_NNP Institute_NNP 's_POS Surveillance_NNP ,_, Epidemiology_NNP ,_, and_CC
        End_NN Results_NNS (_( SEER_NNP )_) Program_NN ._. The_DT objective_NN of_IN our_PRP$ study_NN was_VBD
        to_TO evaluate_VB the_DT diagnostic_JJ accuracy_NN of_IN PSA_NNP testing_NN for_IN
        detecting_VBG prostate_NN cancer_NN in_IN community_NN practice_NN ._.
      
      
        Methods_NNP
        
          Data_NNP collection_NN
          We_PRP collected_VBD computerized_JJ data_NNS from_IN four_CD major_JJ
          clinical_JJ laboratories_NNS in_IN Albuquerque_NNP ,_, New_NNP Mexico_NNP on_IN PSA_NNP
          testing_NN occurring_VBG from_IN January_NNP 1_CD ,_, 1995_CD through_IN December_NNP
          31_CD ,_, 1997_CD ._. These_DT laboratories_NNS provided_VBD testing_NN services_NNS
          for_IN university_NN ,_, Veterans_NNP Affairs_NNPS ,_, Health_NNP Maintenance_NNP
          Organizations_NNP ,_, and_CC private_JJ plan_NN patients_NNS within_IN the_DT
          four-county_JJ Albuquerque_NNP metropolitan_JJ area_NN ._. Data_NNP included_VBD
          test_NN date_NN ,_, PSA_NNP level_NN ,_, and_CC patient_NN demographics_NNS ,_, including_VBG
          birth_NN date_NN ,_, age_NN at_IN testing_NN ,_, and_CC personal_JJ identifiers_NNS ._.
          Additionally_RB ,_, we_PRP used_VBD the_DT GUESS_NNP program_NN ,_, a_DT validated_JJ
          algorithm_NN developed_VBN at_IN the_DT University_NNP of_IN New_NNP Mexico_NNP ,_, to_TO
          identify_VB ethnic_JJ background_NN based_VBN on_IN surname_NN [_NN 12_CD ]_NN ._. We_PRP
          evaluated_VBD only_RB men_NNS age_VBP 40_CD years_NNS and_CC older_JJR at_IN the_DT time_NN of_IN
          initial_JJ testing_NN ._. The_DT PSA_NNP testing_NN data_NNS were_VBD matched_VBN with_IN
          the_DT NMTR_NNP database_NN to_TO exclude_VB PSA_NNP tests_NNS ordered_VBD for_IN cancer_NN
          surveillance_NN and_CC to_TO identify_VB incident_NN cases_NNS of_IN prostate_NN
          cancer_NN diagnosed_VBN between_IN January_NNP 1_CD ,_, 1995_CD and_CC December_NNP 31_CD ,_,
          1998_CD ._. The_DT NMTR_NNP database_NN provided_VBD information_NN on_IN cancer_NN
          stage_NN ,_, using_VBG the_DT SEER_NNP categories_NNS of_IN local_JJ ,_, regional_JJ ,_, and_CC
          distant_JJ ._. Trained_VBN medical_JJ record_NN abstractors_NNS from_IN the_DT NMTR_NNP
          also_RB collected_VBD data_NNS from_IN area_NN laboratories_NNS on_IN all_DT benign_JJ
          prostate_NN biopsies_NNS during_IN the_DT same_JJ time_NN period_NN ._. The_DT human_JJ
          subjects_NNS committees_NNS of_IN the_DT participating_VBG hospitals_NNS and_CC
          laboratories_NNS approved_VBD the_DT study_NN protocol_NN ._.
        
        
          Data_NNP analysis_NN
          We_PRP evaluated_VBD the_DT diagnostic_JJ accuracy_NN of_IN PSA_NNP testing_NN
          using_VBG subjects_NNS in_IN the_DT PSA-tested_NNP cohort_NN who_WP had_VBD a_DT
          confirmed_VBN diagnosis_NN of_IN incident_NN prostate_NN cancer_NN and_CC using_VBG
          subjects_NNS who_WP underwent_VBD at_IN least_JJS one_CD prostate_NN biopsy_NN and_CC
          were_VBD not_RB diagnosed_VBN with_IN prostate_NN cancer_NN during_IN the_DT study_NN
          period_NN ._. For_IN a_DT subject_NN to_TO be_VB included_VBN in_IN this_DT analysis_NN ,_, we_PRP
          required_VBD that_IN a_DT PSA_NNP result_NN be_VB obtained_VBN within_IN 12_CD months_NNS
          before_IN a_DT cancer_NN diagnosis_NN or_CC a_DT negative_JJ biopsy_NN result_NN ._. If_IN
          a_DT subject_NN had_VBD multiple_JJ negative_JJ biopsies_NNS ,_, we_PRP analyzed_VBD the_DT
          first_JJ biopsy_NN that_WDT could_MD be_VB linked_VBN to_TO a_DT PSA_NNP test_NN within_IN
          the_DT preceding_VBG 12_CD months_NNS ._. If_IN subjects_NNS had_VBD multiple_JJ PSA_NNP
          tests_NNS within_IN 12_CD months_NNS preceding_VBG a_DT negative_JJ biopsy_NN or_CC
          cancer_NN diagnosis_NN ,_, we_PRP analyzed_VBD the_DT first_JJ PSA_NNP test_NN ._.
          Clinical_NNP characteristics_NNS of_IN cases_NNS and_CC controls_NNS were_VBD
          compared_VBN with_IN chi-square_JJ tests_NNS for_IN categorical_JJ variables_NNS
          and_CC either_CC t-tests_JJ or_CC the_DT Mann-_NNP Whitney_NNP U_NNP test_NN for_IN
          continuous_JJ variables_NNS ._. Linear_NNP regression_NN analyses_NNS were_VBD
          used_VBN to_TO test_VB for_IN linear_JJ trends_NNS ._. Statistical_NNP tests_NNS were_VBD
          performed_VBN with_IN the_DT software_NN program_NN Statistica_NNP [_NN 13_CD ]_NN
          ._.
          We_PRP constructed_VBN receiver_NN operating_VBG characteristic_JJ (_( ROC_NNP )_)
          curves_NNS by_IN plotting_VBG sensitivity_NN against_IN 1_CD -_: specificity_NN ._.
          We_PRP estimated_VBD the_DT discriminating_VBG power_NN of_IN PSA_NNP testing_NN by_IN
          determining_VBG the_DT area_NN under_IN the_DT ROC_NNP curve_NN using_VBG the_DT method_NN
          of_IN Hanley_NNP and_CC McNeil_NNP [_NN 14_CD ]_NN ._. ROC_NNP curves_NNS were_VBD constructed_VBN
          for_IN the_DT entire_JJ cohort_NN ,_, for_IN 10_CD -_: year_NN age_NN ranges_NNS ,_, and_CC for_IN
          non-_NN Hispanic_NNP whites_NNS and_CC Hispanics_NNPS ._. We_PRP also_RB constructed_VBN an_DT
          ROC_NNP curve_NN using_VBG only_RB cases_VBZ with_IN localized_JJ cancers_NNS ,_, the_DT
          target_NN of_IN PSA_NNP screening_NN ._.
          PSA_NNP accuracy_NN was_VBD evaluated_VBN according_VBG to_TO standard_JJ
          epidemiologic_JJ definitions_NNS for_IN specificity_NN ,_, sensitivity_NN ,_,
          likelihood_NN ratios_NNS ,_, and_CC predictive_JJ values_NNS [_NN 15_CD ]_NN ._.
          Briefly_NNP ,_, we_PRP defined_VBD sensitivity_NN as_IN the_DT proportion_NN of_IN
          cancer_NN cases_NNS with_IN an_DT elevated_VBD PSA_NNP ;_: specificity_NN is_VBZ the_DT
          proportion_NN of_IN non-cancer_JJ controls_NNS with_IN a_DT normal_JJ PSA_NNP ._. The_DT
          positive_JJ predictive_JJ value_NN of_IN a_DT test_NN is_VBZ the_DT proportion_NN of_IN
          subjects_NNS with_IN an_DT abnormal_JJ test_NN result_NN who_WP have_VBP the_DT target_NN
          disorder_NN ._. The_DT negative_JJ predictive_JJ value_NN is_VBZ the_DT proportion_NN
          of_IN subjects_NNS with_IN a_DT normal_JJ test_NN result_NN who_WP do_VBP not_RB have_VB the_DT
          target_NN disorder_NN ._. A_DT likelihood_NN ratio_NN compares_VBZ the_DT
          proportion_NN of_IN people_NNS with_IN and_CC without_IN the_DT target_NN disorder_NN
          within_IN a_DT stratum_NN of_IN diagnostic_JJ test_NN results_NNS ._. Likelihood_NNP
          ratios_NNS provide_VBP a_DT magnitude_NN of_IN probability_NN revision_NN using_VBG
          a_DT version_NN of_IN Bayes_NNP '_POS theorem_NN :_:
          Post-test_NNP odds_NNS for_IN the_DT target_NN disorder_NN =_SYM Pre-test_NNP odds_NNS
          for_IN the_DT target_NN disorder_NN ×_NN Likelihood_NNP ratio_NN for_IN diagnostic_JJ
          test_NN results_NNS
          The_DT diagnostic_JJ accuracy_NN of_IN PSA_NNP testing_NN was_VBD further_RBR
          evaluated_VBN by_IN examining_VBG different_JJ PSA_NNP cutpoints_NNS ,_, by_IN
          stratifying_VBG analyses_NNS into_IN five_CD age_NN ranges_NNS (_( 40_CD to_TO 49_CD ,_, 50_CD
          to_TO 59_CD ,_, 60_CD to_TO 69_CD ,_, 70_CD to_TO 79_CD ,_, and_CC ≥_NN 80_CD years_NNS )_) ,_, and_CC by_IN using_VBG
          age-specific_JJ PSA_NNP reference_NN ranges_NNS [_NN 16_CD ]_NN ._. We_PRP also_RB looked_VBD
          at_IN stratum-specific_JJ likelihood_NN ratios_NNS and_CC predictive_JJ
          values_NNS for_IN the_DT following_VBG PSA_NNP strata_NN :_: <_NN 2_CD ng_NN /_NN ml_NN ,_, ≥_NN 2_CD -_:
          4_CD ng_NN /_NN ml_NN ,_, >_NN 4_CD -_: 10_CD ng_NN /_NN ml_NN ,_, >_NN 10_CD -_: 20_CD ng_NN /_NN ml_NN ,_, and_CC >_NN
          20_CD ng_NN /_NN ml_NN ._. An_DT Excel_NNP spreadsheet_NN developed_VBN by_IN Peirce_NNP and_CC
          Cornell_NNP was_VBD used_VBN to_TO compute_VB likelihood_NN ratios_NNS and_CC 95_CD %_NN
          confidence_NN intervals_NNS for_IN different_JJ PSA_NNP cutpoints_NNS and_CC
          test-result_JJ strata_NN [_NN 17_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Subject_NNP characteristics_NNS
          We_PRP obtained_VBD data_NNS on_IN 41_CD ,_, 261_CD men_NNS without_IN a_DT previous_JJ
          diagnosis_NN of_IN prostate_NN cancer_NN who_WP underwent_VBD PSA_NNP testing_NN at_IN
          Albuquerque_NNP ,_, New_NNP Mexico_NNP laboratories_NNS between_IN January_NNP 1_CD ,_,
          1995_CD and_CC December_NNP 31_CD ,_, 1997_CD ._. By_IN the_DT end_NN of_IN 1998_CD ,_, 2_CD ,_, 620_CD
          (_( 6_CD ._. 3_LS %_NN )_) of_IN the_DT testing_NN cohort_NN had_VBD undergone_VBN a_DT prostate_NN
          biopsy_NN within_IN 12_CD months_NNS following_VBG an_DT initial_JJ PSA_NNP test_NN and_CC
          930_CD (_( 2_CD ._. 3_LS %_NN )_) of_IN these_DT men_NNS were_VBD diagnosed_VBN with_IN prostate_NN
          cancer_NN ._. The_DT median_JJ age_NN at_IN testing_NN was_VBD 61_CD years_NNS (_( 25_CD
          thpercentile_NN 52_CD ,_, 75_CD thpercentile_NN 69_CD )_) ;_: 63_CD ._. 4_LS %_NN of_IN the_DT men_NNS
          were_VBD non-_NN Hispanic_JJ white_JJ and_CC 28_CD ._. 3_LS %_NN were_VBD Hispanic_JJ ._. The_DT
          median_JJ PSA_NNP value_NN for_IN cancer_NN patients_NNS (_( 7_CD ._. 8_CD ng_NN /_NN ml_NN ,_, 25_CD
          thpercentile_NN 4_CD ._. 9_CD ,_, 75_CD thpercentile_NN 14_CD ._. 2_LS )_) was_VBD significantly_RB
          higher_JJR than_IN the_DT median_JJ value_NN for_IN patients_NNS without_IN cancer_NN
          (_( 5_CD ._. 4_LS ng_NN /_NN ml_NN ,_, 25_CD thpercentile_NN 2_CD ._. 7_CD ng_NN /_NN ml_NN ,_, 75_CD thpercentile_NN
          8_CD ._. 1_LS )_) ,_, P_NN <_NN 0_CD ._. 0001_CD ._. Cancer_NN patients_NNS were_VBD also_RB
          significantly_RB older_JJR ,_, with_IN a_DT median_JJ age_NN of_IN 68_CD years_NNS (_( 25_CD
          thpercentile_NN 63_CD ,_, 75_CD thpercentile_NN 67_CD )_) vs_NNS ._. 66_CD years_NNS (_( 25_CD
          thpercentile_NN 60_CD ,_, 75_CD thpercentile_NN 71_CD )_) ,_, P_NN <_NN 0_CD ._. 0001_CD ._.
        
        
          Diagnostic_NNP accuracy_NN
          The_DT discriminating_VBG power_NN of_IN PSA_NNP testing_NN for_IN detecting_VBG
          prostate_NN cancer_NN ,_, as_IN estimated_VBN by_IN the_DT area_NN under_IN the_DT ROC_NNP
          curve_NN (_( Figure_NN ._. 1_LS )_) ,_, was_VBD 0_CD ._. 67_CD (_( SE_NNP 0_CD ._. 02_CD )_) ._. When_WRB we_PRP analyzed_VBD
          the_DT ROC_NNP curve_NN just_RB using_VBG the_DT 796_CD cases_NNS with_IN localized_JJ
          cancers_NNS ,_, we_PRP found_VBD a_DT similar_JJ area_NN of_IN 0_CD ._. 64_CD (_( SE_NNP 0_CD ._. 01_CD )_) ._. The_DT
          discriminating_VBG power_NN remained_VBD relatively_RB constant_JJ across_IN
          age_NN ranges_NNS ,_, with_IN areas_NNS of_IN 0_CD ._. 70_CD ,_, 0_CD ._. 68_CD ,_, 0_CD ._. 63_CD ,_, 0_CD ._. 65_CD ,_, and_CC
          0_CD ._. 69_CD for_IN men_NNS in_IN their_PRP$ 40_CD s_VBZ ,_, 50_CD s_VBZ ,_, 60_CD s_VBZ ,_, 70_CD s_VBZ ,_, and_CC 80_CD s_VBZ ,_,
          respectively_RB ._. The_DT area_NN under_IN the_DT ROC_NNP curve_NN was_VBD 0_CD ._. 66_CD for_IN
          non-_NN Hispanic_JJ whites_NNS compared_VBN to_TO 0_CD ._. 69_CD for_IN Hispanics_NNPS ._.
          Estimates_NNS for_IN sensitivity_NN ,_, specificity_NN ,_, and_CC predictive_JJ
          values_NNS for_IN different_JJ PSA_NNP cutpoints_NNS ,_, stratified_JJ by_IN age_NN
          range_NN ,_, are_VBP reported_VBN in_IN Tables_NNP 1_CD and_CC 2_CD ._. Data_NNP are_VBP presented_VBN
          for_IN men_NNS in_IN their_PRP$ 50_CD s_VBZ and_CC 60_CD s_VBZ in_IN Table_NNP 1_CD ,_, and_CC for_IN men_NNS in_IN
          their_PRP$ 70_CD s_VBZ and_CC all_DT age_NN groups_NNS combined_VBN (_( including_VBG men_NNS in_IN
          their_PRP$ 40_CD s_VBZ and_CC men_NNS 80_CD years_NNS and_CC older_JJR )_) in_IN Table_NNP 2_CD ._. For_IN the_DT
          standard_JJ PSA_NNP cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN ,_, test_NN sensitivity_NN was_VBD
          86_CD %_NN and_CC specificity_NN was_VBD 33_CD %_NN ._. With_IN this_DT cutpoint_NN ,_, the_DT
          likelihood_NN ratio_NN for_IN a_DT positive_JJ test_NN was_VBD 1_CD ._. 28_CD (_( 95_CD %_NN CI_NNP
          1_CD ._. 23_CD to_TO 1_CD ._. 34_CD )_) and_CC 0_CD ._. 42_CD (_( 95_CD %_NN CI_NNP 0_CD ._. 36_CD to_TO 0_CD ._. 50_CD )_) for_IN a_DT
          negative_JJ test_NN ._.
          Raising_VBG the_DT cutpoint_NN to_TO 10_CD ng_NN /_NN ml_NN decreased_VBD the_DT
          sensitivity_NN to_TO 38_CD %_NN while_IN specificity_NN increased_VBD to_TO 84_CD %_NN ._.
          The_DT associated_VBN likelihood_NN ratio_NN for_IN a_DT positive_JJ test_NN was_VBD
          2_CD ._. 38_CD (_( 95_CD %_NN CI_NNP 2_CD ._. 08_CD to_TO 2_CD ._. 72_CD )_) and_CC 0_CD ._. 74_CD (_( 95_CD %_NN CI_NNP 0_CD ._. 70_CD to_TO 0_CD ._. 78_CD )_)
          for_IN a_DT negative_JJ test_NN ._. Lowering_NNP the_DT cutpoint_NN to_TO 2_CD ng_NN /_NN ml_NN
          increased_VBD the_DT sensitivity_NN to_TO 95_CD %_NN but_CC dropped_VBD specificity_NN
          to_TO 20_CD %_NN ._. At_IN this_DT cutpoint_NN the_DT likelihood_NN ratio_NN for_IN a_DT
          positive_JJ test_NN was_VBD 1_CD ._. 19_CD (_( 95_CD %_NN CI_NNP 1_CD ._. 15_CD to_TO 1_CD ._. 22_CD )_) and_CC 0_CD ._. 25_CD
          (_( 95_CD %_NN CI_NNP 0_CD ._. 19_CD to_TO 0_CD ._. 34_CD )_) for_IN a_DT negative_JJ test_NN ._. The_DT predictive_JJ
          value_NN for_IN PSA_NNP was_VBD significantly_RB correlated_JJ with_IN PSA_NNP
          cutpoint_NN level_NN ,_, P_NN =_SYM 0_CD ._. 01_CD for_IN linear_JJ trend_NN ,_, ranging_VBG from_IN
          39_CD %_NN for_IN PSA_NNP levels_NNS ≥_NN 2_CD ng_NN /_NN ml_NN to_TO 78_CD %_NN for_IN PSA_NNP levels_NNS ≥_NN 20_CD
          ng_NN /_NN ml_NN ._.
          Stratum-specific_NNP likelihood_NN ratios_NNS and_CC predictive_JJ
          values_NNS are_VBP presented_VBN in_IN Table_NNP 3_CD ._. We_PRP found_VBD that_IN the_DT
          likelihood_NN ratio_NN for_IN PSA_NNP levels_NNS between_IN 4_CD and_CC 10_CD ng_NN /_NN ml_NN
          was_VBD statistically_RB equivalent_JJ to_TO 1_CD ,_, indicating_VBG that_IN no_DT
          significant_JJ probability_NN revision_NN occurred_VBD with_IN testing_NN ._.
          PSA_NNP values_NNS less_JJR than_IN 2_CD ng_NN /_NN ml_NN or_CC greater_JJR than_IN 20_CD ng_NN /_NN ml_NN
          produced_VBD the_DT largest_JJS probability_NN revisions_NNS for_IN detecting_VBG
          prostate_NN cancer_NN ._.
          Table_NNP 4_CD shows_VBZ the_DT diagnostic_JJ accuracy_NN for_IN PSA_NNP levels_NNS ≥_NN
          4_CD ng_NN /_NN ml_NN stratified_JJ by_IN age_NN ._. The_DT sensitivity_NN of_IN PSA_NNP
          significantly_RB increased_VBD with_IN age_NN ,_, going_VBG from_IN 75_CD %_NN for_IN men_NNS
          in_IN their_PRP$ 40_CD s_VBZ to_TO 90_CD %_NN in_IN men_NNS 70_CD years_NNS and_CC older_JJR ,_, P_NN =_SYM 0_CD ._. 03_CD
          for_IN linear_JJ trend_NN ._. However_RB ,_, specificity_NN significantly_RB
          decreased_VBD from_IN 56_CD %_NN in_IN the_DT younger_JJR men_NNS to_TO 27_CD %_NN in_IN older_JJR
          men_NNS ,_, P_NN =_SYM 0_CD ._. 03_CD for_IN linear_JJ trend_NN ._. With_IN age-specific_JJ
          references_NNS ranges_NNS (_( Table_NNP 5_LS )_) we_PRP found_VBD that_IN ,_, compared_VBN to_TO
          the_DT traditional_JJ cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN ,_, sensitivity_NN was_VBD
          higher_JJR in_IN the_DT younger_JJR age_NN ranges_NNS and_CC specificity_NN was_VBD
          higher_JJR in_IN the_DT older_JJR age_NN ranges_NNS ._. Overall_RB ,_, however_RB ,_, the_DT
          magnitudes_NNS of_IN the_DT likelihood_NN ratios_NNS with_IN age-specific_JJ
          reference_NN ranges_NNS were_VBD similar_JJ to_TO those_DT found_VBD with_IN the_DT 4_CD
          ng_NN /_NN ml_NN cutpoint_NN ,_, except_IN for_IN higher_JJR likelihood_NN ratios_NNS
          following_VBG negative_JJ tests_NNS in_IN men_NNS 70_CD years_NNS and_CC older_JJR ._. The_DT
          sensitivity_NN and_CC specificity_NN of_IN PSA_NNP ,_, using_VBG either_CC a_DT
          cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN or_CC age-specific_JJ reference_NN ranges_NNS ,_, did_VBD
          not_RB differ_VB significantly_RB between_IN non-_NN Hispanic_JJ white_JJ and_CC
          Hispanic_JJ men_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        We_PRP evaluated_VBD the_DT diagnostic_JJ performance_NN of_IN PSA_NNP testing_NN
        using_VBG a_DT community-based_JJ analysis_NN of_IN men_NNS who_WP underwent_VBD
        prostate_NN biopsy_NN within_IN 12_CD months_NNS of_IN PSA_NNP testing_NN ._. Data_NNP were_VBD
        analyzed_VBN for_IN 930_CD prostate_NN cancer_NN cases_NNS and_CC 1690_CD controls_NNS
        ages_NNS 40_CD years_NNS and_CC older_JJR ._. The_DT area_NN under_IN the_DT ROC_NNP curve_NN was_VBD
        0_CD ._. 67_CD ,_, indicating_VBG fair_JJ discriminating_VBG power_NN for_IN detecting_VBG
        prostate_NN cancer_NN ._. PSA_NNP testing_NN performed_VBN equally_RB well_RB in_IN
        detecting_VBG localized_JJ cancers_NNS and_CC in_IN detecting_VBG cancers_NNS across_IN
        all_DT age_NN ranges_NNS and_CC in_IN non-_NN Hispanic_JJ white_JJ and_CC Hispanic_JJ men_NNS ._.
        The_DT standard_JJ cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN had_VBD a_DT sensitivity_NN of_IN 86_CD %_NN
        and_CC a_DT specificity_NN of_IN 33_CD %_NN and_CC was_VBD most_RBS sensitive_JJ -_: but_CC least_JJS
        specific_JJ -_: for_IN older_JJR men_NNS ._. The_DT 4_CD ng_NN /_NN ml_NN cutpoint_NN was_VBD
        associated_VBN with_IN a_DT likelihood_NN ratio_NN for_IN a_DT positive_JJ test_NN of_IN
        1_CD ._. 28_CD and_CC 0_CD ._. 42_CD for_IN a_DT negative_JJ test_NN ,_, representing_VBG only_RB
        moderate_JJ probability_NN revisions_NNS [_NN 18_CD ]_NN ._. PSA_NNP values_NNS <_NN 2_CD
        ng_NN /_NN ml_NN or_CC greater_JJR than_IN 20_CD ng_NN /_NN ml_NN were_VBD associated_VBN with_IN large_JJ
        probability_NN revisions_NNS ._. Likelihood_NNP ratios_NNS did_VBD not_RB change_VB
        substantially_RB when_WRB we_PRP used_VBD age-specific_JJ reference_NN ranges_NNS ,_,
        though_IN test_NN sensitivity_NN decreased_VBD with_IN increasing_VBG age_NN while_IN
        specificity_NN increased_VBD ._. Lowering_NNP the_DT PSA_NNP cutpoint_NN to_TO 2_CD ng_NN /_NN ml_NN
        raised_VBD the_DT sensitivity_NN to_TO 97_CD %_NN but_CC led_VBN to_TO an_DT 80_CD %_NN false_JJ
        positive_JJ rate_NN ._.
        Most_JJS previous_JJ reports_NNS from_IN the_DT urologic_JJ literature_NN
        provided_VBD similar_JJ estimates_NNS for_IN the_DT discriminating_VBG power_NN of_IN
        the_DT PSA_NNP test_NN ._. Areas_NNS under_IN the_DT ROC_NNP curve_NN have_VBP been_VBN reported_VBN
        to_TO range_VB from_IN 0_CD ._. 65_CD to_TO 0_CD ._. 77_CD in_IN case_NN series_NN comprised_VBN of_IN
        patients_NNS enrolled_VBD in_IN screening_NN trials_NNS [_NN 4_CD 19_CD 20_CD 21_CD ]_NN or_CC
        followed_VBN in_IN urologic_JJ practice_NN [_NN 22_CD ]_NN ._. Among_IN urologic_JJ
        studies_NNS ,_, we_PRP found_VBD only_RB Labrie_NNP and_CC colleagues_NNS reporting_VBG a_DT
        substantially_RB higher_JJR area_NN under_IN the_DT ROC_NNP curve_NN :_: 0_CD ._. 88_CD (_( SE_NNP
        0_CD ._. 03_CD )_) [_NN 23_CD ]_NN ._. However_RB ,_, biopsies_NNS were_VBD performed_VBN only_RB when_WRB
        digital_JJ rectal_NN or_CC transrectal_NN ultrasound_NN examinations_NNS were_VBD
        abnormal_JJ ,_, which_WDT would_MD inflate_VB the_DT apparent_JJ sensitivity_NN of_IN
        an_DT elevated_VBD PSA_NNP level_NN ._. Gann_NNP and_CC colleagues_NNS reported_VBD an_DT area_NN
        under_IN the_DT ROC_NNP curve_NN of_IN 0_CD ._. 83_CD in_IN a_DT nested_JJ case-control_JJ study_NN
        of_IN Physicians_NNPS Health_NNP Study_NNP participants_NNS with_IN 10_CD years_NNS of_IN
        follow-up_JJ [_NN 24_CD ]_NN ._. Stored_NNP serum_NN from_IN cases_NNS clinically_RB
        diagnosed_VBN with_IN prostate_NN cancer_NN and_CC age-matched_JJ controls_NNS
        were_VBD assayed_JJ for_IN PSA_NNP ._. However_RB ,_, the_DT specificity_NN of_IN PSA_NNP was_VBD
        probably_RB overestimated_JJ because_IN asymptomatic_JJ men_NNS were_VBD
        unlikely_JJ to_TO be_VB biopsied_JJ ._.
        We_PRP identified_VBD only_RB three_CD population-based_JJ studies_NNS
        evaluating_VBG PSA_NNP testing_NN performance_NN [_NN 23_CD 25_CD 26_CD ]_NN ._. The_DT two_CD
        urologic_JJ studies_NNS [_NN 23_CD 25_CD ]_NN randomly_RB selected_VBD men_NNS from_IN
        either_DT electoral_JJ rolls_NNS or_CC census_NN records_NNS and_CC invited_VBD them_PRP
        to_TO have_VB prostate_NN examinations_NNS ._. However_RB ,_, neither_DT study_NN used_VBD
        PSA_NNP levels_NNS as_IN a_DT criterion_NN for_IN biopsy_NN thus_RB confounding_VBG the_DT
        reported_VBD predictive_JJ values_NNS with_IN results_NNS from_IN digital_JJ rectal_NN
        examinations_NNS and_CC transrectal_NN ultrasonography_NN ._. Jacobsen_NNP and_CC
        colleagues_NNS conducted_VBD a_DT retrospective_NN ,_, case-control_JJ study_NN
        analyzing_VBG 177_CD prostate_NN cancer_NN cases_NNS diagnosed_VBN in_IN Olmsted_NNP
        County_NNP ,_, Minnesota_NNP in_IN the_DT early_JJ 1990_CD s_VBZ [_NN 26_CD ]_NN ._. PSA_NNP was_VBD
        highly_RB discriminating_VBG with_IN an_DT area_NN under_IN the_DT ROC_NNP curve_NN of_IN
        0_CD ._. 94_CD (_( SE_NNP ,_, 0_CD ._. 01_CD )_) for_IN all_DT patients_NNS ._. Age-stratified_NNP analyses_NNS
        showed_VBD that_IN the_DT discriminating_VBG power_NN remained_VBD high_JJ across_IN
        all_DT age_NN groups_NNS ,_, even_RB for_IN men_NNS in_IN their_PRP$ 70_CD s_VBZ ._. Test_NN sensitivity_NN
        was_VBD approximately_RB 85_CD %_NN for_IN all_DT age_NN groups_NNS ,_, though_IN
        specificity_NN decreased_VBD from_IN 98_CD %_NN among_IN men_NNS in_IN their_PRP$ 50_CD s_VBZ to_TO
        81_CD %_NN among_IN men_NNS in_IN their_PRP$ 70_CD s_VBZ ._.
        Methodologic_NNP differences_NNS in_IN study_NN design_NN may_MD explain_VB the_DT
        disparities_NNS in_IN the_DT results_NNS between_IN the_DT New_NNP Mexico_NNP and_CC
        Minnesota_NNP cohorts_NNS ._. Controls_NNP in_IN Olmsted_NNP County_NNP were_VBD drawn_VBN
        from_IN a_DT longitudinal_NN Mayo_NNP Clinic_NNP study_NN on_IN the_DT natural_JJ
        history_NN of_IN lower_JJR urinary_JJ tract_NN symptoms_NNS ._. Men_NN with_IN initial_JJ
        PSA_NNP elevations_NNS >_NN 4_CD ng_NN /_NN ml_NN or_CC an_DT abnormal_JJ DRE_NNP were_VBD
        biopsied_JJ and_CC cancer_NN cases_NNS were_VBD excluded_VBN ._. However_RB ,_, men_NNS with_IN
        normal_JJ PSA_NNP and_CC DRE_NNP results_NNS did_VBD not_RB undergo_VB biopsy_NN ,_, thus_RB
        potentially_RB inflating_VBG estimates_NNS for_IN specificity_NN ._.
        Sensitivity_NNP may_MD have_VB been_VBN higher_JJR if_IN urologists_NNS at_IN the_DT Mayo_NNP
        Clinic_NNP had_VBD a_DT lower_JJR false_JJ negative_JJ biopsy_NN rate_NN than_IN did_VBD New_NNP
        Mexico_NNP urologists_NNS ._.
        Our_PRP$ estimates_NNS for_IN the_DT sensitivity_NN (_( 86_CD %_NN )_) ,_, specificity_NN
        (_( 33_CD %_NN )_) ,_, and_CC positive_JJ predictive_JJ value_NN (_( 41_CD %_NN )_) for_IN PSA_NNP levels_NNS ≥_NN
        4_CD ng_NN /_NN ml_NN were_VBD similar_JJ to_TO previously_RB reported_VBD values_NNS ._. In_IN the_DT
        urologic_JJ literature_NN ,_, sensitivities_NNS ranged_VBD from_IN 67_CD %_NN to_TO 90_CD %_NN ,_,
        specificities_NNS ranged_VBD from_IN 28_CD %_NN to_TO 59_CD %_NN ,_, and_CC positive_JJ
        predictive_JJ values_NNS ranged_VBD from_IN 30_CD %_NN to_TO 43_CD %_NN [_NN 9_CD 10_CD 11_CD 19_CD 20_CD 27_CD
        28_CD ]_NN ._. However_RB ,_, almost_RB all_DT of_IN the_DT published_VBN studies_NNS ,_,
        including_VBG our_PRP$ own_JJ ,_, are_VBP flawed_VBN by_IN potential_JJ work-up_JJ bias_NN
        because_IN men_NNS with_IN elevated_VBD PSA_NNP levels_NNS were_VBD significantly_RB
        more_RBR likely_JJ to_TO be_VB biopsied_JJ ._. In_IN our_PRP$ cohort_NN ,_, men_NNS with_IN a_DT PSA_NNP
        level_NN ≥_NN 4_CD ng_NN /_NN ml_NN had_VBD a_DT 15_CD -_: fold_VB increased_VBN rate_NN of_IN biopsy_NN
        compared_VBN to_TO men_NNS with_IN normal_JJ values_NNS ._.
        Accurately_NNP estimating_VBG the_DT true_JJ and_CC false_JJ negative_JJ rates_NNS
        for_IN PSA_NNP requires_VBZ that_IN men_NNS with_IN normal_JJ PSA_NNP values_NNS undergo_VBP
        biopsy_NN ,_, but_CC we_PRP found_VBD only_RB one_CD small_JJ urologic_JJ series_NN where_WRB
        all_DT PSA-tested_NNP subjects_NNS were_VBD subsequently_RB biopsied_JJ ._.
        Vallencian_NNP and_CC colleagues_NNS biopsied_JJ 100_CD consecutive_JJ men_NNS with_IN
        normal_JJ or_CC non-suspicious_JJ digital_JJ rectal_NN examinations_NNS and_CC
        detected_VBD only_RB 14_CD cancers_NNS ,_, none_NN with_IN PSA_NNP levels_NNS below_IN 10_CD
        ng_NN /_NN ml_NN [_NN 29_CD ]_NN ._. The_DT Gann_NNP study_NN provided_VBD the_DT least_RBS biased_VBN
        estimate_NN of_IN sensitivity_NN and_CC specificity_NN ,_, but_CC even_RB these_DT
        results_NNS were_VBD limited_JJ because_IN asymptomatic_JJ cancers_NNS would_MD not_RB
        have_VB been_VBN detected_VBN [_NN 24_CD ]_NN ._. Additionally_RB ,_, serum_NN was_VBD stored_VBN
        for_IN about_IN 10_CD years_NNS and_CC PSA_NNP is_VBZ not_RB completely_RB stable_JJ [_NN 30_CD 31_CD
        ]_NN ._.
        Modifications_NNS of_IN the_DT PSA_NNP level_NN have_VBP been_VBN proposed_VBN to_TO
        improve_VB the_DT discriminating_VBG power_NN of_IN the_DT test_NN ._. Oesterling_NNP
        and_CC colleagues_NNS developed_VBD age-specific_JJ PSA_NNP reference_NN ranges_NNS
        that_WDT lowered_VBD the_DT cutpoint_NN in_IN younger_JJR men_NNS ,_, to_TO increase_VB
        sensitivity_NN ,_, and_CC raised_VBD the_DT cutpoint_NN in_IN older_JJR men_NNS in_IN order_NN
        to_TO increase_VB specificity_NN [_NN 16_CD ]_NN ._. We_PRP found_VBD that_IN using_VBG
        age-specific_JJ reference_NN ranges_NNS did_VBD not_RB substantially_RB change_VB
        likelihood_NN ratios_NNS for_IN prostate_NN cancer_NN ,_, though_IN we_PRP confirmed_VBD
        that_DT sensitivity_NN would_MD increase_VB in_IN younger_JJR men_NNS and_CC
        specificity_NN would_MD increase_VB in_IN older_JJR men_NNS ._.
        The_DT age-specific_JJ reference_NN ranges_NNS have_VBP been_VBN further_RBR
        modified_VBN for_IN racial_JJ differences_NNS in_IN PSA_NNP and_CC cancer_NN risk_NN [_NN 32_CD
        ]_NN ._. Because_IN African-_NNP Americans_NNPS have_VBP an_DT increased_VBN incidence_NN
        of_IN prostate_NN cancer_NN and_CC higher_JJR PSA_NNP levels_NNS at_IN diagnosis_NN ,_, the_DT
        age-specific_JJ reference_NN ranges_NNS have_VBP been_VBN adjusted_VBN to_TO
        maintain_VB a_DT high_JJ sensitivity_NN [_NN 32_CD 33_CD 34_CD ]_NN ._. Our_PRP$ study_NN cohort_NN
        had_VBD too_RB few_JJ African-_NNP Americans_NNPS for_IN a_DT subgroup_NN analysis_NN ,_, but_CC
        we_PRP were_VBD able_JJ to_TO compare_VB non-_NN Hispanic_JJ white_NN with_IN Hispanic_JJ
        men_NNS ._. We_PRP found_VBD that_IN PSA_NNP testing_NN discriminated_JJ equally_RB well_RB
        for_IN Hispanics_NNPS and_CC non-_NN Hispanic_JJ whites_NNS and_CC that_IN PSA_NNP
        cutpoints_NNS do_VBP not_RB need_VB to_TO be_VB adjusted_VBN for_IN Hispanics_NNPS ._. We_PRP are_VBP
        unaware_JJ of_IN any_DT other_JJ studies_NNS comparing_VBG the_DT performance_NN of_IN
        PSA_NNP testing_NN between_IN non-_NN Hispanic_JJ white_JJ and_CC Hispanic_JJ men_NNS ,_,
        though_IN Abdalla_NNP and_CC colleagues_NNS have_VBP reported_VBN similar_JJ PSA_NNP
        levels_NNS in_IN non-_NN Hispanic_JJ white_JJ and_CC Hispanic_JJ men_NNS with_IN and_CC
        without_IN prostate_NN cancer_NN [_NN 35_CD 36_CD ]_NN ._.
        Some_DT investigators_NNS are_VBP now_RB recommending_VBG that_IN lower_JJR PSA_NNP
        cutpoints_NNS should_MD be_VB used_VBN as_IN an_DT indication_NN for_IN prostate_NN
        biopsy_NN [_NN 37_CD 38_CD 39_CD ]_NN ._. Catalona_NNP and_CC colleagues_NNS detected_VBD
        cancer_NN in_IN 22_CD %_NN of_IN men_NNS biopsied_JJ with_IN PSA_NNP levels_NNS between_IN 2_CD ._. 6_CD
        to_TO 4_CD ng_NN /_NN ml_NN [_NN 37_CD ]_NN and_CC Lodding_NNP and_CC colleagues_NNS detected_VBD
        cancers_NNS in_IN 13_CD %_NN of_IN men_NNS with_IN PSA_NNP values_NNS between_IN 3_CD to_TO 4_CD ng_NN /_NN ml_NN
        [_NN 39_CD ]_NN ._. We_PRP found_VBD that_IN lowering_VBG the_DT cutpoint_NN to_TO 2_CD ng_NN /_NN ml_NN ,_,
        while_IN greatly_RB increasing_VBG sensitivity_NN ,_, led_VBN to_TO an_DT 80_CD %_NN false_JJ
        positive_JJ rate_NN ._.
        Aside_RB from_IN work-up_JJ bias_NN ,_, there_EX were_VBD some_DT other_JJ important_JJ
        limitations_NNS in_IN our_PRP$ study_NN ._. We_PRP do_VBP not_RB know_VB the_DT indications_NNS
        for_IN testing_NN or_CC results_NNS from_IN digital_JJ rectal_NN examinations_NNS ._.
        The_DT positive_JJ predictive_JJ value_NN of_IN 41_CD %_NN that_IN we_PRP found_VBD for_IN a_DT
        PSA_NNP cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN was_VBD at_IN the_DT high_JJ end_NN of_IN values_NNS
        reported_VBD in_IN screening_NN studies_NNS and_CC cancer_NN was_VBD detected_VBN in_IN
        24_CD %_NN of_IN men_NNS in_IN our_PRP$ cohort_NN with_IN normal_JJ PSA_NNP levels_NNS ._. These_DT
        findings_NNS suggest_VBP that_IN our_PRP$ estimates_NNS for_IN sensitivity_NN and_CC
        specificity_NN may_MD be_VB less_RBR applicable_JJ to_TO a_DT true_JJ screening_NN
        population_NN ._. However_RB ,_, we_PRP believe_VBP that_IN our_PRP$ results_NNS more_RBR
        accurately_RB reflect_VB community_NN testing_NN practices_NNS than_IN the_DT
        data_NNS reported_VBN by_IN urologic_JJ series_NN of_IN volunteer_NN subjects_NNS ._.
        Finally_RB ,_, our_PRP$ study_NN cohort_NN was_VBD largely_RB comprised_VBN of_IN
        non-_NN Hispanic_JJ white_JJ and_CC Hispanic_JJ men_NNS ._. Data_NNP suggest_VBP that_IN the_DT
        PSA_NNP assay_NN may_MD perform_VB differently_RB in_IN African-_NNP Americans_NNPS and_CC
        our_PRP$ results_NNS may_MD not_RB be_VB generalizable_JJ to_TO other_JJ populations_NNS [_NN
        32_CD ]_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ community-based_JJ study_NN showed_VBD that_IN PSA_NNP testing_NN had_VBD
        fair_JJ discriminating_VBG power_NN for_IN detecting_VBG prostate_NN cancer_NN
        with_IN an_DT area_NN under_IN the_DT ROC_NNP curve_NN of_IN 0_CD ._. 67_CD ._. PSA_NNP testing_NN had_VBD
        similar_JJ discriminating_VBG power_NN for_IN detecting_VBG localized_JJ
        cancers_NNS ,_, and_CC it_PRP performed_VBD equally_RB well_RB across_IN age_NN ranges_NNS
        and_CC in_IN different_JJ ethnic_JJ groups_NNS ._. The_DT PSA_NNP cutpoint_NN of_IN 4_CD ng_NN /_NN ml_NN
        was_VBD sensitive_JJ but_CC relatively_RB non-specific_JJ and_CC likelihood_NN
        ratios_NNS for_IN this_DT cutpoint_NN demonstrated_VBN only_RB moderate_JJ
        probability_NN revisions_NNS ._. Although_IN age-specific_JJ reference_NN
        ranges_NNS improved_VBD sensitivity_NN in_IN younger_JJR men_NNS and_CC specificity_NN
        in_IN older_JJR men_NNS ,_, they_PRP did_VBD not_RB substantially_RB change_VB likelihood_NN
        ratios_NNS for_IN cancer_NN ._. Lowering_NNP the_DT PSA_NNP cutpoint_NN below_IN 4_CD ng_NN /_NN ml_NN
        increased_VBD test_NN sensitivity_NN but_CC markedly_RB decreased_VBD
        specificity_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        RMH_NNP conceived_VBD of_IN the_DT study_NN ,_, obtained_VBN research_NN funding_NN ,_,
        analyzed_VBD data_NNS ,_, and_CC drafted_VBD the_DT manuscript_NN ._. FDG_NNP helped_VBD
        design_NN the_DT study_NN and_CC draft_VB the_DT manuscript_NN ._. MA-C_NNP collected_VBD
        data_NNS ,_, created_VBD analytic_JJ files_NNS ,_, and_CC helped_VBD analyze_VB data_NNS ._. WCH_NNP
        helped_VBD create_VB analytic_JJ files_NNS and_CC analyze_VB the_DT data_NNS ._. CRK_NNP
        helped_VBD obtain_VB research_NN funding_NN and_CC supported_VBN data_NNS
        collection_NN and_CC analysis_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
